Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-5902 at AACR 102nd Annual Meeting
ROCKVILLE, Md.--(BUSINESS WIRE)--Mar 30, 2011 - Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-5902 during a poster session at the American Association for Cancer Research (AACR) 102nd Annual Meeting being held in Orlando, Florida, April 2-6, 2011, at the Orange County Convention Center.
The Company will present data on the anti-tumor activity of RX-5902 in a poster (abstract #1371) entitled, “Anti-tumor activity of a new quinoxalinyl-piperazine compound (RX-5902),” on Monday, April 4, 2011, during the “Drug Design and Lead Optimization 1” poster session from 8:00 am – 12:00 pm EDT in Exhibit Hall A4-C, Poster Section 16.
For more information on the AACR conference, please visit www.aacr.org.
RX-5902 is an orally available new chemical entity that both exhibits potent anti-tumor properties and significantly increases survival in several xenograft models. The compound also exhibits strong anti-proliferative activity against known anti-cancer drug-resistance cancer cells, as well as a synergistic effect with known anti-cancer drugs such as paclitaxel, doxorubicin, gemcitabine, 5-fluorouracil and cisplatin. RX-5902 is part of a growing pipeline of pre-clinical oncology compounds that Rexahn is developing to provide higher efficacy, resulting in improved survival and quality of life for patients.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ – all potential best in class therapeutics – and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information about Rexahn, please visit www.rexahn.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this press release speak only as of the date of this press release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: Rexahn Pharmaceuticals
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
Posted: March 2011